RAC

RACURA ONCOLOGY LTD - News & Media

0.00%

$2.05

Market Cap $400.8M

Healthcare Biotechnology

Reach your audience today.

Corporate Spotlight

View the full Corporate Spotlight

Articles & Videos

Inside Racura Oncology: Strategy, clinical milestones, and the year ahead

It's been a huge year for Racura Oncology, and CY26 only promises to get bigger as the biotech developer leaves behind its "Race" name.

17 Dec 2025 14:02 (AEDT)

Race Oncology's placement-at-a-premium rewarded as shares jump +8%

Race Oncology has completed its recent A$3.2M placement – something that shareholders on the HotCopper forums typically don't like.

09 Dec 2025 13:22 (AEDT)

Race Oncology launches fresh myeloid leukemia and lung cancer trials with RC220

Race Oncology has sought to expand the total addressable markets it can reach with its cancer drug RC220 with a new launch this week.

17 Nov 2025 11:58 (AEDT)

Race Oncology indentifies 'primary mechanism of action' of its lead anticancer candidate

Race Oncology has announced the discovery of the primary mechanism of action of its lead anticancer candidate, (E,E)-bisantrene (RCDS1).

02 Oct 2025 09:14 (AEST)

Race Oncology's +180% month on month rally continues with fresh approval from Korean drug regulator

Race Oncology has received approval for an investigational new drug from Korea's health and drug regulator MFDS.

24 Sep 2025 13:44 (AEST)

Race Oncology accelerates gamechanging cancer drug

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s @safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time.Listen to the HotCopper podcast for in-d...

02 Jul 2025 09:48 (AEST)

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

14 Mar 2025 10:10 (AEDT)

Race identifies 39 new molecules with potential to inhibit cancer-associated protein

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

21 Nov 2024 11:39 (AEDT)

Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors.In work performed under contract by Labcorp in the United States, Rac...

13 Jun 2024 11:12 (AEST)

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug bisantrene

14 May 2024 09:56 (AEST)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last $2.05		Change 0.000(0.00%)		Mkt cap ! $400.8M

Open	High	Low	Volume
$2.06	$2.08	$2.00	44.44K

Buyers (Bids)

Vol.	Price($)
1834	$2.03

Sellers (Offers)

Price($)	Vol.
$2.05	62

Last trade - 16.10pm 24/07/2026 (20 minute delay)

RAC (ASX) Chart